Appetite

VeriNew Transforms Healthcare Accessibility Through Innovative Telehealth Platform

Retrieved on: 
Wednesday, February 28, 2024

VeriNew is poised to disrupt the healthcare landscape by offering tailored care plans and direct-to-patient prescription services, thereby setting a new standard in healthcare delivery.

Key Points: 
  • VeriNew is poised to disrupt the healthcare landscape by offering tailored care plans and direct-to-patient prescription services, thereby setting a new standard in healthcare delivery.
  • By prioritizing individualized attention and comprehensive support, VeriNew ensures that every patient receives the personalized care they deserve, paving the way for a more inclusive and empowering healthcare experience.
  • This is weight loss redefined – effective, and accessible.”
    VeriNew's innovative platform integrates advanced telehealth services with a comprehensive approach to healthcare, transcending mere treatment.
  • VeriNew is a direct-to-patient healthcare technology company with a mission of helping patients reach their wellness goals through convenient and effective care.

BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

Retrieved on: 
Tuesday, February 27, 2024

“In clinical trials, TEVIMBRA has demonstrated its potential to improve survival for patients with gastric and gastroesophageal junction cancer.

Key Points: 
  • “In clinical trials, TEVIMBRA has demonstrated its potential to improve survival for patients with gastric and gastroesophageal junction cancer.
  • Median progression-free survival for TEVIMBRA plus chemotherapy was 6.9 months vs. 6.2 months respectively; (HR: 0.78 [95% CI: 0.67, 0.90]).
  • The safety profile for TEVIMBRA in combination with chemotherapy was manageable and in line with the known safety profile of anti-PD-1 antibodies.
  • A BLA for the treatment of patients with advanced or metastatic ESCC after prior chemotherapy is also under review by the FDA.

Record Breaking Global PRT Market Activity Seen in 2023, Totaling Over $105 Billion in UK and US

Retrieved on: 
Monday, February 19, 2024

The Monitor, which analyzes industry trends and market outlooks, showed an estimated £50 billion of pension liabilities were secured with insurers in the UK and $45 billion in the US.

Key Points: 
  • The Monitor, which analyzes industry trends and market outlooks, showed an estimated £50 billion of pension liabilities were secured with insurers in the UK and $45 billion in the US.
  • The Boots Pension Scheme , another Legal & General transaction, plus two pension schemes of the RSA Group constituted the largest ever single and overall transactions, respectively.
  • Five transactions of over £2.5 billion were announced compared to just one the previous year and only ten others between 2014 and 2022.
  • In the UK alone, annualized volumes are projected to settle in the region of £50-60 billion, a significant increase from the average of £31 billion seen in the five years prior to 2023.

Crystal appoints Navin Gupta, Former Ripple Managing Director, as Chief Executive Officer

Retrieved on: 
Monday, February 19, 2024

Crystal , a leading blockchain intelligence firm focused on compliance and risk monitoring for cryptocurrencies, announced the appointment of Navin Gupta as its new Chief Executive Officer.

Key Points: 
  • Crystal , a leading blockchain intelligence firm focused on compliance and risk monitoring for cryptocurrencies, announced the appointment of Navin Gupta as its new Chief Executive Officer.
  • Gupta takes over from Marina Khaustova, who moves into the new position of Chief Operations Officer at Crystal.
  • View the full release here: https://www.businesswire.com/news/home/20240218207539/en/
    Gupta joins Crystal from Ripple, where he successfully drove growth for the firm in the MEA and South Asian markets.
  • The product offers real-time indirect risk assessment, monitoring over 50,000 entities and organizations and offers proprietary training programs for professional cybercrime investigators.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024

These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.

Key Points: 
  • These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.
  • GLP-1 medicines – also known as glucagon-like peptide-1 receptor agonist (GLP-1 RA) - are increasingly being prescribed for people with Type 2 diabetes as they provide glycemic benefit and support weight loss.
  • "While treating my patients, I've observed that when we've added a CGM, like the FreeStyle Libre technology, to their GLP-1 therapy, we see even better glycemic control.
  • To maximize the benefits of GLP-1 medicines, it's worth considering the combination of a CGM to support people who live with Type 2 diabetes."

Pickleball Kingdom To Be Everywhere In Washington

Retrieved on: 
Monday, March 4, 2024

SEATTLE, March 4, 2024 /PRNewswire/ -- Pickleball Kingdom, the leading name in the rapidly growing sport of pickleball, is thrilled to announce a significant expansion across the entire state of Washington.

Key Points: 
  • SEATTLE, March 4, 2024 /PRNewswire/ -- Pickleball Kingdom, the leading name in the rapidly growing sport of pickleball, is thrilled to announce a significant expansion across the entire state of Washington.
  • Opening the whole state is a milestone for Pickleball Kingdom, the sport of pickleball, but mostly for the State of Washington."
  • Pickleball Kingdom is now on a mission to revolutionize how the sport is played and experienced through its proprietary indoor clubs in Washington.
  • With the expansion, Pickleball Kingdom is actively seeking ambitious franchise partners who are eager to be at the forefront of the pickleball movement.

Automotive ADAS Sensors Market Anticipates Significant Growth with Emphasis on Safety Features and Luxury Vehicles - Global Outlook and Forecasts to 2029

Retrieved on: 
Monday, March 4, 2024

In the rapidly evolving automotive industry, the importance of safety and luxury features has been brought into sharp focus, with the global automotive Advanced Driver Assistance Systems (ADAS) sensors market experiencing robust growth.

Key Points: 
  • In the rapidly evolving automotive industry, the importance of safety and luxury features has been brought into sharp focus, with the global automotive Advanced Driver Assistance Systems (ADAS) sensors market experiencing robust growth.
  • This brisk pace is largely attributed to the increasing consumer demand for safety features and the growing integration of ADAS sensors in the luxury vehicle segment.
  • Within the market's ecosystem, safety is paramount, and the high demand for safety features is propelling the growth of ADAS sensors, such as radar, lidar, cameras, and ultrasonic sensors.
  • Who are the key players in the global automotive ADAS sensors market?

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Retrieved on: 
Friday, March 1, 2024

RARITAN, N.J., March 1, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test.1 This FDA action converts the May 2021 accelerated approval of RYBREVANT® to a full approval based on the confirmatory Phase 3 PAPILLON study.

Key Points: 
  • The approval of RYBREVANT plus chemotherapy heralds a promising new first-line treatment option for patients newly diagnosed with non-small cell lung cancer where their driver mutation is an EGFR exon 20 insertion," said Marcia Horn**, Executive Director of the Exon 20 Group and CEO of ICAN, International Cancer Advocacy Network.
  • We've seen first-hand the extended survival that Exon 20 Group patients experienced on RYBREVANT plus chemotherapy in the PAPILLON study, and we're delighted that this historic treatment option, which specifically targets the EGFR exon 20 insertion mutation, has been approved."
  • "RYBREVANT plus chemotherapy is the first targeted approach approved for the first-line treatment of patients with NSCLC with EGFR exon 20 insertion mutations.
  • We look forward to building on this latest milestone as we continue to accelerate our transformative lung cancer portfolio."